DE2161588C3 - Mittel zur Behandlung von Hyperlipoproteinämien - Google Patents
Mittel zur Behandlung von HyperlipoproteinämienInfo
- Publication number
- DE2161588C3 DE2161588C3 DE2161588A DE2161588A DE2161588C3 DE 2161588 C3 DE2161588 C3 DE 2161588C3 DE 2161588 A DE2161588 A DE 2161588A DE 2161588 A DE2161588 A DE 2161588A DE 2161588 C3 DE2161588 C3 DE 2161588C3
- Authority
- DE
- Germany
- Prior art keywords
- acid
- cholesterol
- lowering
- effect
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims description 14
- 208000020346 hyperlipoproteinemia Diseases 0.000 title claims description 9
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims description 8
- 229960001214 clofibrate Drugs 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 35
- 230000000694 effects Effects 0.000 description 28
- 238000012360 testing method Methods 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 15
- 150000002632 lipids Chemical class 0.000 description 15
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 6
- 235000001968 nicotinic acid Nutrition 0.000 description 6
- 239000011664 nicotinic acid Substances 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229960003512 nicotinic acid Drugs 0.000 description 5
- 229940126062 Compound A Drugs 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- -1 2- (p-chlorophenoxy) -2-methylpropionic acid ester Chemical class 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940125753 fibrate Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000001278 effect on cholesterol Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- AYTIDAUZTBCCKN-UHFFFAOYSA-N 2,3-dihydroxy-4-oxo-4-(pyridin-3-ylmethoxy)butanoic acid Chemical compound OC(=O)C(O)C(O)C(=O)OCC1=CC=CN=C1 AYTIDAUZTBCCKN-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- RSMSFENOAKAUJU-UHFFFAOYSA-L bis[[2-(4-chlorophenoxy)-2-methylpropanoyl]oxy]aluminum;hydrate Chemical compound O.C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)O[Al]OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 RSMSFENOAKAUJU-UHFFFAOYSA-L 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical class O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003899 tartaric acid esters Chemical class 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE792421D BE792421A (fr) | 1971-12-11 | Agent pour le traitement des hyperlipoproteinemies et son procede de preparation | |
| DE2161588A DE2161588C3 (de) | 1971-12-11 | 1971-12-11 | Mittel zur Behandlung von Hyperlipoproteinämien |
| ZA728251A ZA728251B (en) | 1971-12-11 | 1972-11-21 | Composition for the treatment of hyperlipoproteinaemia |
| IL40912A IL40912A (en) | 1971-12-11 | 1972-11-24 | Composition for the treatment of hyperlipoproteinaemia containing a pyridine and a propionic acid derivative |
| GB5570472A GB1356094A (en) | 1971-12-11 | 1972-12-01 | Pharmaceutical and veterinary compositions for the treatment of hyperlipoproteinaemia |
| FR7243400A FR2162493B1 (https=) | 1971-12-11 | 1972-12-06 | |
| BR8624/72A BR7208624D0 (pt) | 1971-12-11 | 1972-12-07 | Processo para a preparacao de uma composicao contendo uma combinacao de substancias ativas |
| DD167405A DD102583A5 (https=) | 1971-12-11 | 1972-12-08 | |
| HUME1573A HU167337B (https=) | 1971-12-11 | 1972-12-08 | |
| NL7216788.A NL159579B (nl) | 1971-12-11 | 1972-12-11 | Werkwijze ter bereiding van een preparaat met lipoproteine- spiegel verlagende werking; op basis van een clofibrine- zuurester en een 3-pyridylcarbinolderivaat en het onder toepassing daarvan verkregen gevormde preparaat. |
| CA158,568A CA989307A (en) | 1971-12-11 | 1972-12-11 | Agent for the treatment of hyperlipoproteinemias and process for the preparation thereof |
| AT1049172A AT327373B (de) | 1971-12-11 | 1972-12-11 | Verfahren zur herstellung pharmazeutischer zubereitungen |
| AU49918/72A AU466300B2 (en) | 1971-12-11 | 1972-12-11 | Composition for the treatment of hyperlipoproteinaemia |
| MY129/77A MY7700129A (en) | 1971-12-11 | 1977-12-30 | Pharmaceutical and veterinary compositions for the treatment of hyperlipoproteinaemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2161588A DE2161588C3 (de) | 1971-12-11 | 1971-12-11 | Mittel zur Behandlung von Hyperlipoproteinämien |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2161588A1 DE2161588A1 (de) | 1973-06-20 |
| DE2161588B2 DE2161588B2 (de) | 1976-05-26 |
| DE2161588C3 true DE2161588C3 (de) | 1980-02-14 |
Family
ID=5827712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2161588A Expired DE2161588C3 (de) | 1971-12-11 | 1971-12-11 | Mittel zur Behandlung von Hyperlipoproteinämien |
Country Status (14)
| Country | Link |
|---|---|
| AT (1) | AT327373B (https=) |
| AU (1) | AU466300B2 (https=) |
| BE (1) | BE792421A (https=) |
| BR (1) | BR7208624D0 (https=) |
| CA (1) | CA989307A (https=) |
| DD (1) | DD102583A5 (https=) |
| DE (1) | DE2161588C3 (https=) |
| FR (1) | FR2162493B1 (https=) |
| GB (1) | GB1356094A (https=) |
| HU (1) | HU167337B (https=) |
| IL (1) | IL40912A (https=) |
| MY (1) | MY7700129A (https=) |
| NL (1) | NL159579B (https=) |
| ZA (1) | ZA728251B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2621873B2 (de) | 1976-05-17 | 1980-08-28 | Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren | Arzneimittel zur Behandlung von Hypercholesterinämien |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2502678C3 (de) * | 1975-01-23 | 1981-05-14 | Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren | Arzneimittel zur Behandlung primärer und sekundärer Hyperlipoproteinämien |
| FR2430229A1 (fr) * | 1978-01-16 | 1980-02-01 | Laruelle Claude | Nouvelles compositions pour le traitement des hyperlipoproteinemies et procedes de preparation |
| US4820739A (en) * | 1982-06-28 | 1989-04-11 | Lucta, S.A. | Fat suppressant |
| US4859703A (en) * | 1987-06-15 | 1989-08-22 | Warner-Lambert Company | Lipid regulating compositions |
-
0
- BE BE792421D patent/BE792421A/xx unknown
-
1971
- 1971-12-11 DE DE2161588A patent/DE2161588C3/de not_active Expired
-
1972
- 1972-11-21 ZA ZA728251A patent/ZA728251B/xx unknown
- 1972-11-24 IL IL40912A patent/IL40912A/xx unknown
- 1972-12-01 GB GB5570472A patent/GB1356094A/en not_active Expired
- 1972-12-06 FR FR7243400A patent/FR2162493B1/fr not_active Expired
- 1972-12-07 BR BR8624/72A patent/BR7208624D0/pt unknown
- 1972-12-08 DD DD167405A patent/DD102583A5/xx unknown
- 1972-12-08 HU HUME1573A patent/HU167337B/hu unknown
- 1972-12-11 NL NL7216788.A patent/NL159579B/xx not_active IP Right Cessation
- 1972-12-11 AU AU49918/72A patent/AU466300B2/en not_active Expired
- 1972-12-11 AT AT1049172A patent/AT327373B/de not_active IP Right Cessation
- 1972-12-11 CA CA158,568A patent/CA989307A/en not_active Expired
-
1977
- 1977-12-30 MY MY129/77A patent/MY7700129A/xx unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2621873B2 (de) | 1976-05-17 | 1980-08-28 | Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren | Arzneimittel zur Behandlung von Hypercholesterinämien |
Also Published As
| Publication number | Publication date |
|---|---|
| IL40912A (en) | 1975-11-25 |
| FR2162493A1 (https=) | 1973-07-20 |
| CA989307A (en) | 1976-05-18 |
| HU167337B (https=) | 1975-09-27 |
| DE2161588B2 (de) | 1976-05-26 |
| NL159579B (nl) | 1979-03-15 |
| MY7700129A (en) | 1977-12-31 |
| NL7216788A (https=) | 1973-06-13 |
| GB1356094A (en) | 1974-06-12 |
| DE2161588A1 (de) | 1973-06-20 |
| ZA728251B (en) | 1973-07-25 |
| BE792421A (fr) | 1973-06-07 |
| AU4991872A (en) | 1974-06-13 |
| ATA1049172A (de) | 1975-04-15 |
| FR2162493B1 (https=) | 1975-06-20 |
| IL40912A0 (en) | 1973-01-30 |
| AT327373B (de) | 1976-01-26 |
| DD102583A5 (https=) | 1973-12-20 |
| AU466300B2 (en) | 1975-10-23 |
| BR7208624D0 (pt) | 1973-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2903558C2 (de) | Verwendung von L-Carnitin | |
| DE69735598T2 (de) | Progesterone zur behandlung oder minderung von ischemie in menopause befindlichen frauen, die östrogen bekommen | |
| DE3751761T2 (de) | Penetrationsverbesserer für die transdermale Verabreichung von systemisch wirksamen Arzneimitteln | |
| DD158773A5 (de) | Verfahren zur herstellung neuer glycerol-deri vate | |
| DE2911670A1 (de) | Arzneimittel zur therapeutischen behandlung von peripheren vaskularen erkrankungen | |
| DE2903579A1 (de) | Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel | |
| DE3639378A1 (de) | Acyloxyalkanoylcholin-salze zur linderung und therapie von dementia | |
| DE69826674T2 (de) | Zusammensetzung, l-carnitin oder alkanoyl l-carnitin und langkettige alkanole enthaltend | |
| EP0476113B1 (de) | Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose | |
| DE1915798C3 (de) | Antacidum-Präparat in Form einer wäßrigen Suspension | |
| DE2161588C3 (de) | Mittel zur Behandlung von Hyperlipoproteinämien | |
| DE69131553T2 (de) | Arzneimittel enthaltend Mischungen von höheren primären aliphatischen Alkoholen zur Behandlung von Hypercholesterolämie und Hyperlipoproteinämie Typ II und zur Stimulation des sexuellen Verhaltens bei Tieren und Menschen | |
| DE69937574T2 (de) | Verwendung des pharmazeutischen präparates "histochrome" zur behandlung des akuten herzinfarkts und ischämischer herzerkrankungen | |
| DE60207442T2 (de) | VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTION | |
| DE3035494A1 (de) | Carnitin enthaltendes arzneimittel zur behandlung von hyperlipidaemie und hyperlipoproteinaemie, sowie verwendung von carnitin zur herstellung eines solchen arzneimittels | |
| DE3875324T2 (de) | Dl-5-((2-benzyl-3,4-dihydro-2h-benzopyran-6-yl)methyl)thiazolidin-2,4-dion als antiatherosklerosemittel. | |
| DE2126533A1 (de) | Verfahren zur Herstellung pharma zeutischer Zubereitungen | |
| DE1668171A1 (de) | Verfahren zur herstellung von stabilen waessrigen loesungen neuer komplexer organosiliciumverbindungen | |
| DE2846335A1 (de) | Derivate des d,l- bzw. l-carnitins sowie diese enthaltende arzneimittel | |
| EP0024258A1 (de) | Die Herstellung pharmazeutischer Zusammensetzungen zur Behandlung von Herpes-Infektionen | |
| DE3244806C2 (https=) | ||
| DE2728589B2 (de) | Verwendung von 2-(2,2-disubstituierten)-ÄthylimidazoIinen bei der Bekämpfung von Diabetes | |
| DE69307197T2 (de) | Verwendung von 24,25-Dihydroxyvitamin-D3 zur Herstellung eines Arzneimittel zur Behandlung der Rachitis | |
| DE2038836C3 (de) | Arzneimittel | |
| DE2209526B2 (de) | Coronartherapeutikum in Form von Gelatine-BeiBkapseln |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) |